Apixaban

Pre-clinicalCompleted

0 watching 0 views this week💤 Quiet

Hype Score

Development Stage

Pre-clinical

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Deep Vein Thrombosis

Conditions

Deep Vein Thrombosis, Pulmonary Embolism

Trial Timeline

May 4, 2015 → Oct 7, 2015

NCT ID

NCT02345343

About Apixaban

Apixaban is a pre-clinical stage product being developed by Bristol Myers Squibb for Deep Vein Thrombosis. The current trial status is completed. This product is registered under clinical trial identifier NCT02345343. Target conditions include Deep Vein Thrombosis, Pulmonary Embolism.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (12)

NCT ID	Phase	Status	Start	Completion	Indication
NCT05187286	Pre-clinical	Active	—	—	—
NCT03594045	Phase 2	Terminated	Dec 18, 2018	Oct 30, 2019	Heparin-induced Thrombocytopenia
NCT02958969	Approved	Completed	Feb 28, 2018	Nov 19, 2019	Venous Thromboembolism
NCT03456648	Phase 2	Completed	Sep 25, 2016	Aug 24, 2018	ESRD
NCT02714855	Pre-clinical	Completed	Oct 1, 2015	Dec 1, 2016	Anticoagulation
NCT02345343	Pre-clinical	Completed	May 4, 2015	Oct 7, 2015	Deep Vein Thrombosis
NCT01885585	Pre-clinical	Completed	Jul 1, 2014	May 1, 2015	Venous Thromboembolism
NCT02153424	Pre-clinical	Withdrawn	Apr 1, 2014	Nov 1, 2015	Non-valvular Atrial Fibrillation (NVAF)
NCT02101112	Phase 1	Completed	Mar 1, 2014	May 1, 2014	Thrombosis
NCT01884350	Approved	Completed	Oct 15, 2013	Jan 20, 2016	Non-valvular Atrial Fibrillation
NCT01885598	Pre-clinical	Completed	Jul 10, 2013	Sep 29, 2017	NonValvular Atrial Fibrillation
NCT00252005	Phase 2	Completed	Nov 1, 2005	Feb 1, 2007	Deep-Vein Thrombosis

Competing Products

20 competing products in Deep Vein Thrombosis

See all competitors

Product	Company	Stage	Hype Score
Edoxaban low dose + Edoxaban high dose	Daiichi Sankyo	Phase 1	33
edoxaban tosylate + enoxaparin/unfractionated heparin + warfarin	Daiichi Sankyo	Phase 2	52
Fragmin (dalteparin sodium )	Pfizer	Pre-clinical	22
Fluconazole	Pfizer	Pre-clinical	22
Dalteparin sodium injection + Warfarin	Pfizer	Approved	84
Low Molecular Weight Heparin (dalteparin)	Pfizer	Approved	84
Apixaban + Unfractionated Heparin (UFH) + Warfarin	Pfizer	Phase 3	76
Apixaban	Pfizer	Approved	84
Apixaban	Bristol Myers Squibb	Phase 2	51
Enoxaparin + Placebo + Apixaban + Placebo	Bristol Myers Squibb	Phase 3	76
Enoxaparin + Apixaban + Enoxaparin-matching placebo + Apixaban-matching placebo	Bristol Myers Squibb	Phase 3	76
Enoxaparin + Apixaban + Enoxaparin-matching placebo + Apixaban-matching placebo	Bristol Myers Squibb	Phase 3	76
Enoxaparin	Sanofi	Pre-clinical	22
Clexane	Sanofi	Approved	84
Idrabiotaparinux sodium + Idraparinux sodium + Avidin + Placebo (for Avidin)	Sanofi	Phase 3	76
SanOrg34006 + LMW heparin + Unfractionated heparin + Vitamin K antagonist (VKA)	Sanofi	Phase 3	76
Rivaroxaban (Xarelto, BAY59-7939) + Standard of care	Bayer	Pre-clinical	20
Rivaroxaban (Xarelto, BAY59-7939) + Rivaroxaban (Xarelto, BAY59-7939) + Unfractionated heparin + Warfarin	Bayer	Phase 3	74
Rivaroxaban (Xarelto, BAY59-7939) + Recommended VTE pharmacological treatments according to international guidelines	Bayer	Pre-clinical	20
Triptorelin Acetate 3.75mg intramuscular injection	Ipsen	Pre-clinical	20

Other Products from Bristol Myers Squibb

DeucravacitinibApproved

Aripiprazole + Olanzapine + HaloperidolApproved

Irbesartan + CiprofibrateApproved

Entecavir + Lamivudine Placebo + Lamivudine + Entecavir PlaceboApproved

deucravacitinibApproved